Allergan Recalls Sample Packs of Taytulla 1 mg/20 mcg, Due to Out of Sequence Capsules

Posted on Jun 07, 2018

Allergan issued a voluntary recall in the United States market of one lot of Taytulla® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, 6×28 physicians sample pack. The recalled product, an oral contraceptive indicated for use by women to prevent pregnancy, was distributed to health care providers nationwide. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of Taytulla. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. The affected lot number is 5620706 and has an expiry date of May 2019. Additional details about this recall may be found in the company’s announcement posted to Food and Drug Administration’s (FDA’s) website. Adverse events or quality problems experienced with the use of this product may be reported to FDA’s MedWatch Safety Information and Adverse Event Reporting Program.